search
Back to results

Effects of Pine Cone Extract on Serum IgE Levels in Perennial Rhinitis (PCE)

Primary Purpose

Perennial Allergic Rhinitis

Status
Active
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
pine cone extract
placebo
Sponsored by
University of South Florida
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Perennial Allergic Rhinitis focused on measuring perennial allergic rhinitis

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Subjects with perennial allergic rhinitis with or without seasonal allergic rhinitis
  2. Male or female participants must be 18 years of age or older

Exclusion Criteria:

  1. Subjects receiving subcutaneous allergen immunotherapy or monoclonal anti-IgE (omalizumab)
  2. Subject with hypersensitivity to PPC
  3. Pregnant subjects (lactating post-partum women will be allowed to participate)
  4. Subjects who are unable to cooperate/comply with study procedures or communicate with investigator in order to successfully complete the study
  5. Subjects with severe skin disorders such as atopic dermatitis, dermatographism, psoriasis who could not have allergy skin testing and who have no prior skin testing completed within 3 years
  6. Subjects with an infirmity, disability, or geographical location which seems likely to prevent regular attendance for patient visits

Sites / Locations

  • Usf Asthma Allergy and Immunology Cru

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Placebo Comparator

Arm Label

capsule

placebo capsule

Arm Description

patinets receiveing pine cone extract tablets

patinets receiving placebo

Outcomes

Primary Outcome Measures

Primary Objective ( total serum IgE)
To provide the proof-of-concept that daily administration of Immune Extra ™(each capsule with 16 mg total pine cone extract or 6 mg of PPC) reduces total serum IgE in subjects with rhinitis and sensitivity to perennial allergens, including dust mite (Dermatophagoides pteronyssinus and Dermatophagoides farinae), cockroach, cat, and dog.

Secondary Outcome Measures

Full Information

First Posted
June 7, 2012
Last Updated
May 9, 2023
Sponsor
University of South Florida
search

1. Study Identification

Unique Protocol Identification Number
NCT04024033
Brief Title
Effects of Pine Cone Extract on Serum IgE Levels in Perennial Rhinitis
Acronym
PCE
Official Title
Effects of Pine Cone Extract on Serum IgE Levels in Perennial Rhinitis
Study Type
Interventional

2. Study Status

Record Verification Date
November 2022
Overall Recruitment Status
Active, not recruiting
Study Start Date
March 2011 (Actual)
Primary Completion Date
October 2023 (Anticipated)
Study Completion Date
October 2023 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University of South Florida

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The medicinal properties of pinecones have been used for years to treat a variety of illnesses. In the mouse model, an extract of pine cones, poly-phenylpropanoid-polysaccharide complex (PPC), has been shown to reduce total serum IgE levels as well as decreased production of IL-4, a cytokine associated with allergic disease. In this study, the investigators aim to determine the effects that PPC will have on total serum IgE levels in adult subjects with perennial rhinitis.
Detailed Description
The study will be a parallel two-arm, double-blind design. The 80% power calculation was based upon preliminary data showing a greater than 30% reduction of total serum IgE in PPC recipients. This power calculation concluded that each arm will need a population of 18 subjects. These subjects will be recruited from a clinical practice of 4 academic allergists/immunologists. Seasonal allergy information will be recorded but the data will be analyzed for each group without any correction for seasonal effects. Recruited subjects will sign the consent form, undergo a complete physical exam, and have skin testing repeated if historical skin tests data within three years is unavailable. The historical skin tests must have been performed using the same techniques as those used in the study. A prick skin test method using commercially available extracts will be used and the results graded according to standard criteria with measurements of the wheal and flare compared to the results of a positive control with histamine and a negative control of saline. A positive skin test will be defined as a wheal diameter 3 mm larger than the negative control with a flare of greater than or equal to 10 mm. A nasal mucosal sample will also be obtained from the inferior turbinate with a plastic device (rhinoprobe). This sample will be frozen at the time of collection for future analysis. This procedure will be optional for subjects; if they consent it will be performed at each visit After screening, patients will be randomized to either of the two arms (placebo, or 32mg PPC/d). Patients will be instructed to take one capsule via oral route daily for 8 weeks. Subjects will be treated for two months with measurements of total serum IgE at the initial screening/randomization visit and following two months of treatment. Physical examination will be repeated at each visit. A variance of 5 days will be permitted for follow-up visits. Rescue treatment with oral, non-sedating antihistamine will be permitted and number of doses will be recorded at each follow up visit. No nasal sprays will be allowed during the study. If symptoms are extreme, the study subject will be discontinued from the trial.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Perennial Allergic Rhinitis
Keywords
perennial allergic rhinitis

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
36 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
capsule
Arm Type
Active Comparator
Arm Description
patinets receiveing pine cone extract tablets
Arm Title
placebo capsule
Arm Type
Placebo Comparator
Arm Description
patinets receiving placebo
Intervention Type
Dietary Supplement
Intervention Name(s)
pine cone extract
Intervention Description
pine cone extract capsule
Intervention Type
Other
Intervention Name(s)
placebo
Intervention Description
placebo capsule
Primary Outcome Measure Information:
Title
Primary Objective ( total serum IgE)
Description
To provide the proof-of-concept that daily administration of Immune Extra ™(each capsule with 16 mg total pine cone extract or 6 mg of PPC) reduces total serum IgE in subjects with rhinitis and sensitivity to perennial allergens, including dust mite (Dermatophagoides pteronyssinus and Dermatophagoides farinae), cockroach, cat, and dog.
Time Frame
8 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Subjects with perennial allergic rhinitis with or without seasonal allergic rhinitis Male or female participants must be 18 years of age or older Exclusion Criteria: Subjects receiving subcutaneous allergen immunotherapy or monoclonal anti-IgE (omalizumab) Subject with hypersensitivity to PPC Pregnant subjects (lactating post-partum women will be allowed to participate) Subjects who are unable to cooperate/comply with study procedures or communicate with investigator in order to successfully complete the study Subjects with severe skin disorders such as atopic dermatitis, dermatographism, psoriasis who could not have allergy skin testing and who have no prior skin testing completed within 3 years Subjects with an infirmity, disability, or geographical location which seems likely to prevent regular attendance for patient visits
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Dennis Ledford, M.D.
Organizational Affiliation
Division of Allergy and Immunology, USF
Official's Role
Principal Investigator
Facility Information:
Facility Name
Usf Asthma Allergy and Immunology Cru
City
Tampa
State/Province
Florida
ZIP/Postal Code
33613
Country
United States

12. IPD Sharing Statement

Learn more about this trial

Effects of Pine Cone Extract on Serum IgE Levels in Perennial Rhinitis

We'll reach out to this number within 24 hrs